REFERENCES
1. Charcot JM, Marie P. Sur une forme particulière d’atrophie musculaire progressive souvent familiale débutant par les pieds et les jambes et atteignant plus tard les mains. Paris: Félix Alcan; 1886. pp. 97-138.
2. Tooth HH. The peroneal type of progressive muscular atrophy: a thesis for the degree of M.D. in the university of cambridge - digital collections - national library of medicine. Available from: https://collections.nlm.nih.gov/catalog/nlm:nlmuid-100899256-bk [Last accessed on 13 June 2022].
5. Barreto LC, Oliveira FS, Nunes PS, et al. Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review. Neuroepidemiology 2016;46:157-65.
6. Combarros O, Calleja J, Polo JM, Berciano J. Prevalence of hereditary motor and sensory neuropathy in Cantabria. Acta Neurol Scand 1987;75:9-12.
7. Bird TD. Charcot-Marie-Tooth (CMT) hereditary neuropathy overview. 1998 Sep 28 [updated 2021 Sep 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®[Internet]. Seattle, WA: University of Washington, 1993-2022.
8. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103:259-80.
9. Werheid F, Azzedine H, Zwerenz E, et al. Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene? Brain Behav 2016;6:e00451.
10. Anzalone CL, Nuhanovic S, Olund AP, Carlson ML. Cochlear implantation in Charcot-Marie-Tooth disease: case report and review of the literature. Case Rep Med 2018;2018:1760978.
11. Lerat J, Magdelaine C, Beauvais-Dzugan H, et al. A novel pathogenic variant of NEFL responsible for deafness associated with peripheral neuropathy discovered through next-generation sequencing and review of the literature. J Peripher Nerv Syst 2019;24:139-44.
12. Jani-Acsadi A, Ounpuu S, Pierz K, Acsadi G. Pediatric Charcot-Marie-Tooth disease. Pediatr Clin N Am 2015;62:767-86.
13. Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69:22-33.
14. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562-71.
15. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). Neuromuscul Disord 1991;1:93-7.
16. Lupski JR, de Oca-luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219-32.
17. Gonzaga-Jauregui C, Harel T, Gambin T, et al. Exome sequence analysis suggests that genetic burden contributes to phenotypic variability and complex neuropathy . Cell Rep 2015;12:1169-83.
18. Blair IP, Nash J, Gordon MJ, Nicholson GA. Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet 1996;58:472-6.
19. Ouvrier R. What can we learn from the history of Charcot-Marie-Tooth disease? Dev Med Child Neurol 2010;52:405-6.
20. Magy L, Mathis S, Le Masson G, Goizet C, Tazir M, Vallat JM. Updating the classification of inherited neuropathies: Results of an international survey. Neurology 2018;90:e870-6.
21. Mathis S, Goizet C, Tazir M, et al. Charcot-Marie-Tooth diseases: an update and some new proposals for the classification. J Med Genet 2015;52:681-90.
22. Timmerman V, Strickland AV, Züchner S. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success. Genes 2014;5:13-32.
23. Høyer H, Braathen GJ, Busk ØL, et al. Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next-generation sequencing. Biomed Res Int 2014;2014:210401.
24. Juárez P, Palau F. Neural and molecular features on Charcot-Marie-Tooth disease plasticity and therapy. Neural Plast 2012;2012:171636.
25. Cohen E, Bonne G, Rivier F, Hamroun D. The 2022 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2021;31:1313-57.
26. Rossor AM, Evans MR, Reilly MM. A practical approach to the genetic neuropathies. Pract Neurol 2015;15:187-98.
27. Miller LJ, Saporta AS, Sottile SL, Siskind CE, Feely SM, Shy ME. Strategy for genetic testing in Charcot-Marie-disease. Acta Myol 2011;30:109-16.
28. Cortese A, Wilcox JE, Polke JM, et al. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. Neurology 2020;94:e51-61.
29. Yubero D, Natera-de Benito D, Pijuan J, et al. The increasing impact of translational research in the molecular diagnostics of neuromuscular diseases. Int J Mol Sci 2021;22:4274.
30. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
31. Young P, De Jonghe P, Stögbauer F, Butterfass-Bahloul T. Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2008;1:CD006052.
32. Sackley C, Disler PB, Turner-stokes L, et al. Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev 2009;8:CD003908.
33. Guillebastre B, Calmels P, Rougier PR. Assessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth disease. Am J Phys Med Rehabil 2011;90:619-27.
34. Jani-Acsadi A, Krajewski K, Shy ME. Charcot-Marie-Tooth neuropathies: diagnosis and management. Semin Neurol 2008;28:185-94.
35. Burns J, Crosbie J, Ouvrier R, Hunt A. Effective orthotic therapy for the painful cavus foot: a randomized controlled trial. J Am Podiatr Med Assoc 2006;96:205-11.
36. Piscosquito G, Reilly MM, Schenone A, et al. CMT-TRIAAL & CMT-TRAUK Group. Is overwork weakness relevant in Charcot-Marie-Tooth disease? J Neurol Neurosurg Psychiatry 2014;85:1354-8.
37. Beals TC, Nickisch F. Charcot-Marie-Tooth disease and the cavovarus foot. Foot Ankle Clin 2008;13:259-74.
39. Herrmann DN. Experimental therapeutics in hereditary neuropathies: the past, the present, and the future. Neurotherapeutics 2008;5:507-15.
40. zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007;61:61-72.
41. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65:681-9.
42. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401.
44. Gess B, Baets J, De Jonghe P, Reilly MM, Pareyson D, Young P. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2015;12:CD011952.
45. Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9:1533-7.
46. Attarian S, Young P, Brannagan TH, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis 2021;16:433.
47. d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011;17:968-74.
48. Adalbert R, Kaieda A, Antoniou C, et al. Novel HDAC6 Inhibitors increase tubulin acetylation and rescue axonal transport of mitochondria in a model of Charcot-Marie-Tooth type 2F. ACS Chem Neurosci 2020;11:258-67.
49. Picci C, Wong VSC, Costa CJ, et al. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Exp Neurol 2020;328:113281.
50. Pisciotta C, Saveri P, Pareyson D. Challenges in treating Charcot-Marie-Tooth disease and related neuropathies: current management and future perspectives. Brain Sci 2021;11:1447.
51. Rossaert E, Van Den Bosch L. HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT. Brain Res 2020;1733:146692.
52. Nuevo-Tapioles C, Santacatterina F, Sánchez-Garrido B, et al. Effective therapeutic strategies in a preclinical mouse model of Charcot-Marie-Tooth disease. Hum Mol Genet 2021;30:2441-55.
53. Kagiava A, Karaiskos C, Richter J, et al. AAV9-mediated schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther 2021;28:659-75.
54. Marco A, Cuesta A, Pedrola L, Palau F, Marín I. Evolutionary and structural analyses of GDAP1, involved in Charcot-Marie-Tooth disease, characterize a novel class of glutathione transferase-related genes. Mol Biol Evol 2004;21:176-87.
55. Huber N, Bieniossek C, Wagner KM, et al. Glutathione-conjugating and membrane-remodeling activity of GDAP1 relies on amphipathic C-terminal domain. Sci Rep 2016;6:36930.
56. Chen CX, Li JQ, Dong HL, Liu GL, Bai G, Wu ZY. Identification and functional characterization of novel GDAP1 variants in Chinese patients with Charcot-Marie-Tooth disease. Ann Clin Transl Neurol 2020;7:2381-92.
57. Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 2005;170:1067-78.
58. Pedrola L, Espert A, Valdés-Sánchez T, et al. Cell expression of GDAP1 in the nervous system and pathogenesis of Charcot-Marie-Tooth type 4A disease. J Cell Mol Med 2008;12:679-89.
60. Azzedine H, Ruberg M, Ente D, et al. Variability of disease progression in a family with autosomal recessive CMT associated with a S194X and new R310Q mutation in the GDAP1 gene. Neuromuscul Disord 2003;13:341-6.
61. Manganelli F, Pisciotta C, Nolano M, et al. A novel autosomal dominant GDAP1 mutation in an Italian CMT2 family. J Peripher Nerv Syst 2012;17:351-5.
62. Cantarero L, Juárez-Escoto E, Civera-Tregón A, et al. Mitochondria-lysosome membrane contacts are defective in GDAP1-related Charcot-Marie-Tooth disease. Hum Mol Genet 2021;29:3589-605.
63. Sevilla T, Cuesta A, Chumillas MJ, et al. Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain 2003;126:2023-33.
64. Niemann A, Wagner KM, Ruegg M, Suter U. GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance. Neurobiol Dis 2009;36:509-20.
65. Noack R, Frede S, Albrecht P, et al. Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Hum Mol Genet 2012;21:150-62.
66. Pla-Martín D, Rueda CB, Estela A, et al. Silencing of the Charcot-Marie-Tooth disease-associated gene GDAP1 induces abnormal mitochondrial distribution and affects Ca2+ homeostasis by reducing store-operated Ca2+ entry. Neurobiol Dis 2013;55:140-51.
67. Pijuan J, Cantarero L, Natera-de Benito D, et al. Mitochondrial dynamics and mitocondria-lysosome contacts in neurogenetic diseases. Front Neurosci 2022;16:784880.
68. Cassereau J, Chevrollier A, Gueguen N, et al. Mitochondrial complex I deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease (CMT2K). Neurogenetics 2009;10:145-50.
69. García-Sobrino T, Blanco-Arias P, Palau F, et al. Phenotypical features of a new dominant GDAP1 pathogenic variant (p.R226del) in axonal Charcot-Marie-Tooth disease. Neuromuscul Disord 2017;27:667-72.
70. González-Sánchez P, Pla-Martín D, Martínez-Valero P, et al. CMT-linked loss-of-function mutations in GDAP1 impair store-operated Ca2+ entry-stimulated respiration. Sci Rep 2017;7:42993.
71. Cassereau J, Chevrollier A, Codron P, et al. Oxidative stress contributes differentially to the pathophysiology of Charcot-Marie-Tooth disease type 2K. Exp Neurol 2020;323:113069.
72. Kleopa KA, Abrams CK, Scherer SS. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease? Brain Res 2012;1487:198-205.
73. Latour P, Gonnaud PM, Ollagnon E, et al. SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 2006;11:148-55.
75. Abrams CK. GJB1 disorders: Charcot-Marie-Tooth Neuropathy (CMT1X) and central nervous system phenotypes. 1998 Jun 18 [updated 2020 Feb 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, 1993-2022.
76. Siskind CE, Murphy SM, Ovens R, Polke J, Reilly MM, Shy ME. Phenotype expression in women with CMT1X. J Peripher Nerv Syst 2011;16:102-7.
77. Dubourg O, Tardieu S, Birouk N, et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain 2001;124:1958-67.
78. Tsai PC, Chen CH, Liu AB, et al. Mutational analysis of the 5' non-coding region of GJB1 in a Taiwanese cohort with Charcot-Marie-Tooth neuropathy. J Neurol Sci 2013;332:51-5.
79. Hahn AF, Ainsworth PJ, Bolton CF, Bilbao JM, Vallat JM. Pathological findings in the x-linked form of Charcot-Marie-Tooth disease: a morphometric and ultrastructural analysis. Acta Neuropathol 2001;101:129-39.
80. Abrams CK, Freidin M. GJB1-associated X-linked Charcot-Marie-Tooth disease, a disorder affecting the central and peripheral nervous systems. Cell Tissue Res 2015;360:659-73.
81. Altevogt BM, Kleopa KA, Postma FR, Scherer SS, Paul DL. Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems. J Neurosci 2002;22:6458-70.
82. Balice-Gordon RJ, Bone LJ, Scherer SS. Functional gap junctions in the schwann cell myelin sheath. J Cell Biol 1998;142:1095-104.
83. Chandross KJ, Kessler JA, Cohen RI, et al. Altered connexin expression after peripheral nerve injury. Mol Cell Neurosci 1996;7:501-18.
84. Scherer S, Deschenes S, Xu Y, Grinspan J, Fischbeck K, Paul D. Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci 1995;15:8281-94.
85. Sutor B, Schmolke C, Teubner B, Schirmer C, Willecke K. Myelination defects and neuronal hyperexcitability in the neocortex of connexin 32-deficient mice. Cereb Cortex 2000;10:684-97.
86. Beauvais K, Furby A, Latour P. Clinical, electrophysiological and molecular genetic studies in a family with X-linked dominant Charcot-Marie-Tooth neuropathy presenting a novel mutation in GJB1 Promoter and a rare polymorphism in LITAF/SIMPLE. Neuromuscul Disord 2006;16:14-8.
87. Houlden H, Girard M, Cockerell C, et al. Connexin 32 promoter P2 mutations: a mechanism of peripheral nerve dysfunction. Ann Neurol 2004;56:730-4.
88. Gonzaga-Jauregui C, Zhang F, Towne CF, Batish SD, Lupski JR. GJB1/Connexin 32 whole gene deletions in patients with X-linked Charcot-Marie-Tooth disease. Neurogenetics 2010;11:465-70.
89. Bicego M, Morassutto S, Hernandez VH, et al. Selective defects in channel permeability associated with Cx32 mutations causing X-linked Charcot-Marie-Tooth disease. Neurobiol Dis 2006;21:607-17.
90. Abrams CK, Islam M, Mahmoud R, Kwon T, Bargiello TA, Freidin MM. Functional requirement for a highly conserved charged residue at position 75 in the gap junction protein connexin 32. J Biol Chem 2013;288:3609-19.
91. Jeng LJ, Balice-Gordon RJ, Messing A, Fischbeck KH, Scherer SS. The effects of a dominant connexin32 mutant in myelinating Schwann cells. Mol Cell Neurosci 2006;32:283-98.
92. Zimoń M, Baets J, Almeida-Souza L, et al. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet 2012;44:1080-3.
93. Peeters K, Chamova T, Tournev I, Jordanova A. Axonal neuropathy with neuromyotonia: there is a HINT. Brain 2017;140:868-77.
94. Rauchenzauner M, Frühwirth M, Hecht M, Kofler M, Witsch-Baumgartner M, Fauth C. A Novel variant in the HINT1 gene in a girl with autosomal recessive axonal neuropathy with neuromyotonia: thorough neurological examination gives the clue. Neuropediatrics 2016;47:119-22.
95. Caetano JS, Costa C, Baets J, et al. Autosomal recessive axonal neuropathy with neuromyotonia: a rare entity. Pediatr Neurol 2014;50:104-7.
96. Laššuthová P, Brožková DŠ, Krůtová M, et al. Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy among Czech patients and neuromyotonia is rather an underdiagnosed symptom. Neurogenetics 2015;16:43-54.
97. Kontogeorgiou Z, Voudommatis C, Kartanou C, et al. HINT1-related neuropathy in Greek patients with Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2021;26:444-8.
98. Chou TF, Sham YY, Wagner CR. Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity. Biochemistry 2007;46:13074-9.
99. Ouvrier R, Mcleod J, Morgan G, Wise G, Conchin T. Hereditary motor and sensory neuropathy of neuronal type with onset in early childhood. J Neurol Sci 1981;51:181-97.
100. Lee M, Park CH, Chung HK, et al. Cerebral white matter abnormalities in patients with charcot-marie-tooth disease. Ann Neurol 2017;81:147-51.
101. Larrea D, Pera M, Gonnelli A, et al. MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics. Hum Mol Genet 2019;28:1782-800.
102. Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study. Brain 2020;143:3589-602.
103. Bombelli F, Stojkovic T, Dubourg O, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol 2014;71:1036-42.
104. Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011;76:1690-6.
105. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science 2012;337:1062-5.
106. Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008;456:605-10.
107. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. Science 2004;305:858-62.
108. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009;18:R169-76.
109. Leal NS, Schreiner B, Pinho CM, et al. Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide production. J Cell Mol Med 2016;20:1686-95.
110. Filadi R, Greotti E, Turacchio G, Luini A, Pozzan T, Pizzo P. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. Proc Natl Acad Sci USA 2015;112:E2174-81.
111. Merkwirth C, Langer T. Mitofusin 2 builds a bridge between ER and mitochondria. Cell 2008;135:1165-7.
112. Vielhaber S, Debska-Vielhaber G, Peeva V, et al. Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol 2013;125:245-56.
113. Amiott EA, Lott P, Soto J, et al. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations. Exp Neurol 2008;211:115-27.
114. Loiseau D, Chevrollier A, Verny C, et al. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol 2007;61:315-23.
115. Chandhok G, Lazarou M, Neumann B. Structure, function, and regulation of mitofusin-2 in health and disease. Biol Rev Camb Philos Soc 2018;93:933-49.
116. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010;11:872-84.
117. El Fissi N, Rojo M, Aouane A, et al. Mitofusin gain and loss of function drive pathogenesis in. Drosophila 2018;19:e45241.
118. Tomaselli PJ, Kapoor M, Cortese A, Polke JM, Rossor AM, Reilly MM. Severe cognitive impairment in a patient with CMT2A. J Peripher Nerv Syst 2018;23:147-8.
119. Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. Cell Death Dis 2018;9:330.
120. Otani Y, Ohno N, Cui J, Yamaguchi Y, Baba H. Upregulation of large myelin protein zero leads to Charcot-Marie-Tooth disease-like neuropathy in mice. Commun Biol 2020;3:121.
121. Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta 2015;1852:667-78.
122. Shy ME, Jáni A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-84.
123. Raasakka A, Ruskamo S, Kowal J, et al. Molecular structure and function of myelin protein P0 in membrane stacking. Sci Rep 2019;9:642.
124. Luo X, Sharma D, Inouye H, et al. Cytoplasmic domain of human myelin protein zero likely folded as beta-structure in compact myelin. Biophys J 2007;92:1585-97.
125. Bai Y, Wu X, Brennan KM, et al. Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. Ann Clin Transl Neurol 2018;5:445-55.
126. Chance PF, Alderson MK, Leppig KA, et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993;72:143-51.
127. Bort S, Nelis E, Timmerman V, et al. Mutational analysis of the MPZ, PMP22 and Cx32 genes in patients of Spanish ancestry with Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies. Hum Genet 1997;99:746-54.
128. Braathen GJ, Sand JC, Lobato A, Høyer H, Russell MB. Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 2011;18:39-48.
129. Karadima G, Floroskufi P, Koutsis G, Vassilopoulos D, Panas M. Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patients. Clin Genet 2011;80:497-9.
130. Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. Orphanet J Rare Dis 2014;9:38.
131. Boutary S, Echaniz-Laguna A, Adams D, et al. Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. Transl Res 2021;227:100-11.
132. Li J, Parker B, Martyn C, Natarajan C, Guo J. The PMP22 gene and its related diseases. Mol Neurobiol 2013;47:673-98.
133. Yuan JH, Hashiguchi A, Okamoto Y, et al. Clinical and mutational spectrum of Japanese patients with recessive variants in SH3TC2. J Hum Genet 2018;63:281-7.
134. Pérez-Garrigues H, Sivera R, Vílchez JJ, Espinós C, Palau F, Sevilla T. Vestibular impairment in Charcot-Marie-Tooth disease type 4C. J Neurol Neurosurg Psychiatry 2014;85:824-7.
135. Claramunt R, Sevilla T, Lupo V, et al. The p.R1109X mutation in SH3TC2 gene is predominant in Spanish Gypsies with Charcot-Marie-Tooth disease type 4. Clin Genet 2007;71:343-9.
136. Laššuthová P, Mazanec R, Vondráček P, et al. High frequency of SH3TC2 mutations in Czech HMSN I patients. Clin Genet 2011;80:334-45.
137. Azzedine H, Salih MA. SH3TC2-related hereditary motor and sensory neuropathy. 2008 Mar 31 [updated 2021 Mar 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, 1993-2022.
138. Lupo V, Galindo MI, Martínez-Rubio D, et al. Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway. Hum Mol Genet 2009;18:4603-14.
139. Gouttenoire EA, Lupo V, Calpena E, et al. Sh3tc2 deficiency affects neuregulin-1/ErbB signaling. Glia 2013;61:1041-51.
140. Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet 2020;52:473-81.
141. Dong HL, Li JQ, Liu GL, Yu H, Wu ZY. Biallelic SORD pathogenic variants cause Chinese patients with distal hereditary motor neuropathy. NPJ Genom Med 2021;6:1.
142. Liu X, He J, Yilihamu M, Duan X, Fan D. Clinical and genetic features of biallelic mutations in. SORD 2021;12:733926.
143. Chen B, Zhang Z, Zhang C, et al. Clinical and pathological study of SORD-related distal motor neuropathy caused by novel compound heterozygous mutations in a Chinese patient. Clin Neurol Neurosurg 2022;213:107118.
